119 related articles for article (PubMed ID: 34046035)
1. Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
Aamdal E; Inderberg EM; Ellingsen EB; Rasch W; Brunsvig PF; Aamdal S; Heintz KM; Vodák D; Nakken S; Hovig E; Nyakas M; Guren TK; Gaudernack G
Front Immunol; 2021; 12():663865. PubMed ID: 34046035
[TBL] [Abstract][Full Text] [Related]
2. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.
Lilleby W; Gaudernack G; Brunsvig PF; Vlatkovic L; Schulz M; Mills K; Hole KH; Inderberg EM
Cancer Immunol Immunother; 2017 Jul; 66(7):891-901. PubMed ID: 28391357
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of patients with cutaneous melanoma with telomerase-specific peptides.
Hunger RE; Kernland Lang K; Markowski CJ; Trachsel S; Møller M; Eriksen JA; Rasmussen AM; Braathen LR; Gaudernack G
Cancer Immunol Immunother; 2011 Nov; 60(11):1553-64. PubMed ID: 21681371
[TBL] [Abstract][Full Text] [Related]
4. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.
Prieto PA; Yang JC; Sherry RM; Hughes MS; Kammula US; White DE; Levy CL; Rosenberg SA; Phan GQ
Clin Cancer Res; 2012 Apr; 18(7):2039-47. PubMed ID: 22271879
[TBL] [Abstract][Full Text] [Related]
5. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer.
Brunsvig PF; Aamdal S; Gjertsen MK; Kvalheim G; Markowski-Grimsrud CJ; Sve I; Dyrhaug M; Trachsel S; Møller M; Eriksen JA; Gaudernack G
Cancer Immunol Immunother; 2006 Dec; 55(12):1553-64. PubMed ID: 16491401
[TBL] [Abstract][Full Text] [Related]
6. A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.
Greene JM; Schneble EJ; Jackson DO; Hale DF; Vreeland TJ; Flores M; Martin J; Herbert GS; Hardin MO; Yu X; Wagner TE; Peoples GE
Cancer Immunol Immunother; 2016 Apr; 65(4):383-92. PubMed ID: 26894495
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma.
Gargett T; Abbas MN; Rolan P; Price JD; Gosling KM; Ferrante A; Ruszkiewicz A; Atmosukarto IIC; Altin J; Parish CR; Brown MP
Cancer Immunol Immunother; 2018 Sep; 67(9):1461-1472. PubMed ID: 30014244
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.
Hiniker SM; Reddy SA; Maecker HT; Subrahmanyam PB; Rosenberg-Hasson Y; Swetter SM; Saha S; Shura L; Knox SJ
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):578-88. PubMed ID: 27681753
[TBL] [Abstract][Full Text] [Related]
9. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.
Fenoglio D; Traverso P; Parodi A; Tomasello L; Negrini S; Kalli F; Battaglia F; Ferrera F; Sciallero S; Murdaca G; Setti M; Sobrero A; Boccardo F; Cittadini G; Puppo F; Criscuolo D; Carmignani G; Indiveri F; Filaci G
Cancer Immunol Immunother; 2013 Jun; 62(6):1041-52. PubMed ID: 23591981
[TBL] [Abstract][Full Text] [Related]
10. Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab.
Sodji QH; Gutkin PM; Swetter SM; Reddy SA; Hiniker SM; Knox SJ
Melanoma Manag; 2020 Feb; 7(1):MMT36. PubMed ID: 32399174
[TBL] [Abstract][Full Text] [Related]
11. First-in-human stage III/IV melanoma clinical trial of immune priming agent IFx-Hu2.0.
Markowitz J; Shamblott M; Brohl AS; Sarnaik AA; Eroglu Z; Khushalani NI; Dukes CW; Chamizo A; Bastawrous M; Garcia ET; Delhawi A; Chen PL; De Aquino DB; Sondak VK; Tarhini AA; Kim Y; Lawman P; Pilon-Thomas S
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38657233
[TBL] [Abstract][Full Text] [Related]
12. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.
Dalle S; Mortier L; Corrie P; Lotem M; Board R; Arance AM; Meiss F; Terheyden P; Gutzmer R; Buysse B; Oh K; Brokaw J; Le TK; Mathias SD; Scotto J; Lord-Bessen J; Moshyk A; Kotapati S; Middleton MR
BMC Cancer; 2021 May; 21(1):642. PubMed ID: 34051732
[TBL] [Abstract][Full Text] [Related]
13. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Bajorin DF; Witjes JA; Gschwend JE; Schenker M; Valderrama BP; Tomita Y; Bamias A; Lebret T; Shariat SF; Park SH; Ye D; Agerbaek M; Enting D; McDermott R; Gajate P; Peer A; Milowsky MI; Nosov A; Neif Antonio J; Tupikowski K; Toms L; Fischer BS; Qureshi A; Collette S; Unsal-Kacmaz K; Broughton E; Zardavas D; Koon HB; Galsky MD
N Engl J Med; 2021 Jun; 384(22):2102-2114. PubMed ID: 34077643
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Zakharia Y; McWilliams RR; Rixe O; Drabick J; Shaheen MF; Grossmann KF; Kolhe R; Pacholczyk R; Sadek R; Tennant LL; Smith CM; Kennedy EP; Link CJ; Vahanian NN; Yu J; Shen SS; Brincks EL; Rossi GR; Munn D; Milhem M
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34117113
[TBL] [Abstract][Full Text] [Related]
16. Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
Khasraw M; Weller M; Lorente D; Kolibaba K; Lee CK; Gedye C; I de La Fuente M; Vicente D; Reardon DA; Gan HK; Scott AM; Dussault I; Helwig C; Ojalvo LS; Gourmelon C; Groves M
Neurooncol Adv; 2021; 3(1):vdab058. PubMed ID: 34056607
[TBL] [Abstract][Full Text] [Related]
17. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
Kudo M; Matilla A; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; Tschaika M; Wisniewski T; Sangro B
J Hepatol; 2021 Sep; 75(3):600-609. PubMed ID: 34051329
[TBL] [Abstract][Full Text] [Related]
18. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).
Zhou C; Wu L; Fan Y; Wang Z; Liu L; Chen G; Zhang L; Huang D; Cang S; Yang Z; Zhou J; Zhou C; Li B; Li J; Fan M; Cui J; Li Y; Zhao H; Fang J; Xue J; Hu C; Sun P; Du Y; Zhou H; Wang S; Zhang W
J Thorac Oncol; 2021 Sep; 16(9):1501-1511. PubMed ID: 34048947
[TBL] [Abstract][Full Text] [Related]
19. Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential.
Ellingsen EB; Mangsbo SM; Hovig E; Gaudernack G
Front Immunol; 2021; 12():682492. PubMed ID: 34290704
[TBL] [Abstract][Full Text] [Related]
20. Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases.
Di Giacomo AM; Chiarion-Sileni V; Del Vecchio M; Ferrucci PF; Guida M; Quaglino P; Guidoboni M; Marchetti P; Cutaia O; Amato G; Covre A; Camerini R; Calabrò L; Valente M; Giannarelli D; Mandalà M; Maio M
Clin Cancer Res; 2021 Sep; 27(17):4737-4745. PubMed ID: 34112708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
